Viavi upgraded to Equal Weight from Underweight at Morgan Stanley

Morgan Stanley analyst Meta Marshall upgraded Viavi (VIAV) to Equal Weight from Underweight with a price target of $11, up from $9.30, also discontinuing the firm’s coverage of the stock. The catalyst path that the company’s pending acquisition of the Spirent asset offers Viavi with significant presence in the critical channel emulation market, providing growth opportunities in key technology testing markets and potential accretion, the analyst tells investors in a research note.